# Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma

> **NCT04678791** · NA · UNKNOWN · sponsor: **Peking University Third Hospital** · enrollment: 286 (estimated)

## Conditions studied

- Cervical Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nimotuzumab
- **DRUG:** Cisplatin
- **RADIATION:** External-beam radiation
- **RADIATION:** Brachytherapy

## Key facts

- **NCT ID:** NCT04678791
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12
- **Primary completion:** 2024-12
- **Final completion:** 2025-12
- **Target enrollment:** 286 (ESTIMATED)
- **Last updated:** 2020-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04678791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04678791, "Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04678791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*